-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Insmed, Lowers Price Target to $241

Benzinga·12/18/2025 17:48:56
Listen to the news
TD Cowen analyst Ritu Baral maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $269 to $241.